Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia


I asked bing AI if karxt and cerevance work in the same way:

KarXT and CVN424 are both novel therapeutics, but they work in different ways.

CVN424 is a first-in-class, oral, non-dopaminergic compound developed by Cerevance12. It acts as a potent modulator of a novel target that is selectively expressed in the striatal neurons of the dopamine D2 receptor dependent pathway3. Specifically, CVN424 is a GPR6 inverse agonist12. In a phase 2 trial, CVN424 significantly improved OFF time by 1.3 hours compared with placebo in the high-dose group at 4 weeks1.

On the other hand, KarXT is an investigational oral dual-drug fixed-dose combination of xanomeline and trospium45. It’s undergoing a phase 3 clinical trial for the treatment of schizophrenia4. Xanomeline is a functionally preferring muscarinic M4 and M1 receptor agonist that readily passes into the central nervous system (CNS) to stimulate these receptors in key areas of the brain4. Trospium is a non-selective muscarinic antagonist that does not cross into the CNS and reduces peripheral cholinergic side effects associated with xanomeline4. Unlike direct dopamine D2 and serotonin 5HT2A blocking antipsychotic medications, M4 and M1 receptor stimulation indirectly rebalances dopaminergic and glutamatergic circuits involved in the symptoms associated with neurological and neuropsychiatric diseases such as schizophrenia and Alzheimer’s disease4.

So, while both KarXT and CVN424 are promising treatments for neurological conditions, they target different receptors and have different mechanisms of action. Always consult with your healthcare provider for medical advice about treatments."

They don’t!